Lead Sponsor

Kyowa Kirin Co., Ltd.

Age

15 - No limit years

Sex

ALL

Healthy Volunteers

No

•Patients must be of non-childbearing potential and female patients must have a negative pregnancy test at the Screening Visit
•Histologically and/or cytologically confirmed cancer with ECOG ≤2
•Life expectancy of ≥ 3 months
•Assigned to receive the first cycle of a new multi-day chemotherapy regimen including the daily administration of cytotoxic agent(s) with the emetogenic potential of level 3-5 (Hesketh Classification) on 3-5 days

•Hypersensitivity to adhesive plasters
•Contraindications to 5-HT3 receptor antagonists
•Clinically relevant abnormal laboratory values or hepatic, renal, infectious, neurological or psychiatric disorders or any other major systemic illness at the discretion of the Investigator
•Any cause for nausea and vomiting other than CINV
•Clinically relevant abnormal ECG parameters
•Concomitant radiotherapy of total body, brain or upper abdomen within one week of study entry or planned during the study
•A patient taking a medication to control the symptoms of a brain tumour, brain metastasis or seizure disorder

Related studies

NCT06120764 · Chemotherapy-induced Nausea and Vomiting, Pediatric Cancer

NCT07540169 · Stomach Cancer, Chemotherapy-induced Nausea and Vomiting, and more

NCT05838638 · Neoplasms, Chemotherapy-induced Nausea and Vomiting

NCT07581119 · Chemotherapy-Induced Nausea and Vomiting (CINV)

NCT06331520 · Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy

To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)